136 related articles for article (PubMed ID: 16755174)
1. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
Fishman PN; Pond GR; Moore MJ; Oza A; Burkes RL; Siu LL; Feld R; Gallinger S; Greig P; Knox JJ
Am J Clin Oncol; 2006 Jun; 29(3):225-31. PubMed ID: 16755174
[TBL] [Abstract][Full Text] [Related]
2. Primary adenocarcinoma of the small intestine: presentation, prognostic factors and clinical outcome.
Hong SH; Koh YH; Rho SY; Byun JH; Oh ST; Im KW; Kim EK; Chang SK
Jpn J Clin Oncol; 2009 Jan; 39(1):54-61. PubMed ID: 18997182
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy in advanced small bowel adenocarcinoma.
Locher C; Malka D; Boige V; Lebray P; Elias D; Lasser P; Ducreux M
Oncology; 2005; 69(4):290-4. PubMed ID: 16282708
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy.
Park I; Lee JL; Ryu MH; Kim TW; Sook Lee S; Hyun Park D; Soo Lee S; Wan Seo D; Koo Lee S; Kim MH
Cancer; 2009 Sep; 115(18):4148-55. PubMed ID: 19536892
[TBL] [Abstract][Full Text] [Related]
5. Primary small intestinal malignant tumors: survival analysis of 48 postoperative patients.
Cao J; Zuo Y; Lv F; Chen Z; Li J
J Clin Gastroenterol; 2008 Feb; 42(2):167-73. PubMed ID: 18209587
[TBL] [Abstract][Full Text] [Related]
6. Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
Thomsen Lønborg J; Vilmar A; Mård D; Astrup Jensen S; Sørensen JB
Oncol Rep; 2007 Oct; 18(4):1023-9. PubMed ID: 17786369
[TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
Han JQ; Liu Q; Liang RX; Qu FS; Yan TX; Sun YH; Li XQ
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):470-3. PubMed ID: 17974287
[TBL] [Abstract][Full Text] [Related]
8. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
[TBL] [Abstract][Full Text] [Related]
9. Influence of smoking on histologic type and the efficacy of adjuvant chemotherapy in resected non-small cell lung cancer.
Zhang Z; Xu F; Wang S; Li N; Wang C
Lung Cancer; 2008 Jun; 60(3):434-40. PubMed ID: 18036699
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
[TBL] [Abstract][Full Text] [Related]
11. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy.
Kim JG; Ryoo BY; Park YH; Kim BS; Kim TY; Im YH; Kang YK
Cancer Chemother Pharmacol; 2008 Feb; 61(2):301-7. PubMed ID: 17429626
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
14. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
De Santis M; Bachner M
Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
[TBL] [Abstract][Full Text] [Related]
15. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C
J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048
[TBL] [Abstract][Full Text] [Related]
16. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
[TBL] [Abstract][Full Text] [Related]
18. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Viel E; Demarchi MF; Chaigneau L; Nguyen T; Legat C; Stein U; Thiery-Vuillemin A; Limat S; Pivot X; Borg C
Am J Clin Oncol; 2008 Feb; 31(1):89-94. PubMed ID: 18376234
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal treatment for peritoneal mucinous carcinomatosis of appendiceal origin after operative management: long-term follow-up of the Mayo Clinic experience.
Schomas DA; Miller RC; Donohue JH; Gill S; Thurmes PJ; Haddock MG; Quevedo JF; Gunderson LL
Ann Surg; 2009 Apr; 249(4):588-95. PubMed ID: 19300231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
